Biblioteca Humberto Rosselli Quijano
Información del autor
Autor E Cabrina Campbell |
Documentos disponibles escritos por este autor (1)
Refinar búsqueda
Drug-induced extrapyramidal syndromes / Stanley N. Caroff en Psychiatric Clinics of North America, Año 2016 - Vol.39 - No.3 (Septiembre)
[artículo]
Título : Drug-induced extrapyramidal syndromes : systematic review and meta-analysis Tipo de documento: texto impreso Autores: Stanley N. Caroff, Autor ; E Cabrina Campbell, Autor Fecha de publicación: 2020 Artículo en la página: pp. 391-411 Idioma : Inglés (eng) Idioma original : Inglés (eng) Palabras clave: Fármacos antipsicóticos, Esquizofrenia, Discinesia tardia, Catatonia, Síndrome neuroléptico maligno, Acatisia, Parkinsonismo, Distonía Resumen: The development of drugs to treat psychosis is a fascinating nexus for understanding mechanisms underlying disorders of mind and movement. Although the risk of drug-induced extrapyramidal syndromes has been mitigated by the acceptance of less potent dopamine antagonists, expansive marketing and off-label use has increased the number of susceptible people who may be at risk for these neurologic effects. Link: ./index.php?lvl=notice_display&id=24114
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.3 (Septiembre) . - pp. 391-411[artículo] Drug-induced extrapyramidal syndromes : systematic review and meta-analysis [texto impreso] / Stanley N. Caroff, Autor ; E Cabrina Campbell, Autor . - 2020 . - pp. 391-411.
Idioma : Inglés (eng) Idioma original : Inglés (eng)
in Psychiatric Clinics of North America > Año 2016 - Vol.39 - No.3 (Septiembre) . - pp. 391-411
Palabras clave: Fármacos antipsicóticos, Esquizofrenia, Discinesia tardia, Catatonia, Síndrome neuroléptico maligno, Acatisia, Parkinsonismo, Distonía Resumen: The development of drugs to treat psychosis is a fascinating nexus for understanding mechanisms underlying disorders of mind and movement. Although the risk of drug-induced extrapyramidal syndromes has been mitigated by the acceptance of less potent dopamine antagonists, expansive marketing and off-label use has increased the number of susceptible people who may be at risk for these neurologic effects. Link: ./index.php?lvl=notice_display&id=24114